Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Purchased by Peregrine Capital Management LLC

Posted by Francis Steltz on Jul 2nd, 2026

Peregrine Capital Management LLC raised its stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Free Report) by 15.2% during the first quarter, HoldingsChannel reports. The fund owned 97,117 shares of the company’s stock after acquiring an additional 12,793 shares during the quarter. Peregrine Capital Management LLC’s holdings in Structure Therapeutics were worth $4,681,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. Janney Montgomery Scott LLC acquired a new stake in shares of Structure Therapeutics in the 1st quarter valued at about $329,000. Sterling Capital Management LLC acquired a new position in Structure Therapeutics in the first quarter worth about $28,000. TrueMark Investments LLC increased its holdings in Structure Therapeutics by 1.4% in the first quarter. TrueMark Investments LLC now owns 34,377 shares of the company’s stock valued at $1,657,000 after buying an additional 484 shares during the last quarter. PEAK6 LLC bought a new stake in Structure Therapeutics in the fourth quarter valued at about $553,000. Finally, Flax Pond Capital LLC acquired a new stake in Structure Therapeutics during the fourth quarter valued at approximately $3,389,000. 91.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

GPCR has been the subject of several research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Tuesday, April 21st. Wall Street Zen cut Structure Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. William Blair reiterated an “outperform” rating on shares of Structure Therapeutics in a research note on Monday, March 16th. Wolfe Research initiated coverage on shares of Structure Therapeutics in a report on Thursday, March 26th. They set a “peer perform” rating on the stock. Finally, Leerink Partners restated an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $110.55.

Read Our Latest Stock Analysis on GPCR

Structure Therapeutics Trading Down 2.9%

Shares of NASDAQ GPCR opened at $52.12 on Thursday. The company has a market cap of $3.70 billion, a price-to-earnings ratio of -59.91 and a beta of -1.50. Structure Therapeutics Inc. Sponsored ADR has a 12-month low of $15.80 and a 12-month high of $94.90. The stock’s 50 day simple moving average is $42.13 and its 200 day simple moving average is $57.59.

Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. As a group, equities analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -1.64 earnings per share for the current fiscal year.

Structure Therapeutics Company Profile

(Free Report)

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.